Nicox to Market Sequenom's RetnaGene AMD Test in North America | GenomeWeb

NEW YORK (GenomeWeb News) – Nicox, a company specializing in ophthalmic therapies and diagnostics, will market Sequenom's RetnaGene AMD test in North America, the partners said today.

Under the terms of the agreement, Nicox has gained exclusive North American promotional rights to Sequenom Laboratories' RetnaGene laboratory-developed test, which evaluates a patient's risk of AMD disease progression within 2, 5 and 10 years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.